Physician profile
Cheryl Michelle Belle
NPI 1255423448
$1,419.57
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $153 · 2021: $494 · 2022: $476 · 2023: $38.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $160.10 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $128.27 | 2019-2022 | |
| Amgen INC. | $125.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $102.76 | 2019-2022 | |
| Abbvie INC. | $74.95 | 2021-2023 | Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $72.80 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $70.44 | 2022 | |
| Bioventus LLC | $64.86 | 2020-2022 | |
| Abbott Laboratories | $64.85 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $59.20 | 2019-2022 | |
| Pacira Therapeutics, INC. | $54.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.08 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.25 | 2022 | |
| Lilly USA, LLC | $42.59 | 2019-2022 | |
| Depuy Synthes Sales INC. | $36.86 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $33.97 | 2022 | |
| Astellas Pharma US INC | $26.67 | 2021 | |
| Corium, LLC | $22.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.94 | 2019 | |
| Global Blood Therapeutics, INC. | $19.48 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.46 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.21 | 2021 | |
| Lupin INC. | $15.90 | 2021 | |
| Gilead Sciences, INC. | $14.40 | 2021 | |
| Insulet Corporation | $13.52 | 2019 | |
| Redhill Biopharma INC. | $13.44 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.47 | 2021 | |
| Mylan Specialty L.P. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Belle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.